

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Please report suspected side effects to the MHRA through the Yellow Card Scheme, via the Yellow Card Scheme website [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard), the free Yellow Card app available in Apple App Store or Google Play Store, and also some clinical IT systems for healthcare professionals. Alternatively you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours. You should also report side effects to Roche Products Ltd by emailing the Roche Drug Safety Centre at [welwyn.uk\\_dsc@roche.com](mailto:welwyn.uk_dsc@roche.com) or calling +44 (0) 1707 367554. When reporting please provide as much information as possible. By reporting side effects, you can help provide more information on the safety of this medicine.

This educational material is provided by Roche Products Limited and mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks.

## Contact Information

Date of Enspryng initiation:

Doctor's phone number:

Doctor's name:

Patient's name:

The Roche logo, consisting of the word "Roche" in a blue, sans-serif font inside a blue hexagonal border.

## Important Safety Information for Patients receiving Enspryng® ▼ (satralizumab)

### Patient Card

Show this card to any doctor, nurse, dentist  
or pharmacist involved in your care.

Date of MHRA approval: February 2024

v1.0.3 M-GB-00013911 January 2024

## **Enspryng may make you less able to fight infections.**

Call your doctor or nurse right away if you feel unwell or have signs of infection (with or without a fever) such as:

- chills, feeling tired, muscle aches, cough that will not go away or a sore throat
- skin redness, swelling, tenderness, pain or sores on your body
- diarrhoea, tummy pain, or feeling sick
- burning when you urinate or urinating more often than usual

This is because you may need to receive appropriate treatment and delay your next dose of Enspryng if you have an infection (even a cold) at that time.

---

## **Information for the treating healthcare professional**

This patient has been prescribed Enspryng (satralizumab) - which may make them more susceptible to infection.

- Evaluate immediately if infection is suspected and start appropriate treatment
- Enspryng can reduce the level of some tests used to evaluate a potential infection e.g., blood neutrophil counts, C-reactive protein. Therefore, normalised inflammatory markers should not necessarily be interpreted as absence of infection.
- **Contact the prescribing doctor** as soon as possible – they may need to delay giving Enspryng until the infection is controlled.

---

For more information about Enspryng, read the Summary of Product Characteristics (SmPC) or the Patient Information Leaflet (PIL) at:

If based in Great Britain at:

<https://www.medicines.org.uk/emc>

If based in Northern Ireland at:

<https://www.emcmedicines.com/en-GB/northernireland>

## **Company contact point -**

If you have any questions or problems:

Call: Roche Medical Information on 0800 328 1629

Email: [medinfo.uk@roche.com](mailto:medinfo.uk@roche.com)

Date of MHRA Approval: February 2024

v1.0.3 M-GB-00013911 January 2024